Talaris Therapeutics Announces Closing of Initial Public Offering

Rhea-AI Summary

Talaris Therapeutics, Inc. (Nasdaq: TALS) announced the closure of its initial public offering, raising approximately $150 million by selling 8,825,000 shares at $17.00 each. The shares began trading on Nasdaq on May 7, 2021. Additionally, the underwriters have a 30-day option to purchase up to 1,323,750 additional shares. The funds will support Talaris's development of innovative cell therapies aimed at improving the standard of care in solid organ transplantation and treating severe autoimmune diseases.

Positive

• Raised approximately $150 million from the initial public offering.
• Funds will support innovative cell therapy development.
• Potential to transform care in solid organ transplantation and severe autoimmune diseases.

Negative

• None.

BOSTON and LOUISVILLE, Ky. , May 11, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced the closing of its initial public offering of 8,825,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds of the offering were approximately $150.0 million, before deducting underwriting discounts and commissions and other offering expenses. The shares began trading on the Nasdaq Global Market on May 7, 2021 under the symbol “TALS.” All shares in the offering were offered by Talaris Therapeutics. In addition, the underwriters have a 30-day option to purchase up to an additional 1,323,750 shares of common stock at the initial public offering price less underwriting discounts and commissions.

Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering.

A registration statement relating to these securities has been filed and was declared effective by the Securities and Exchange Commission on May 6, 2021. This offering was made only by means of a written prospectus. Copies of the final prospectus relating to the initial public offering can be obtained, when available, from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbleerink.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-5548, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.

About Talaris Therapeutics

Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders. Talaris maintains corporate offices in Boston, Mass., and its cell processing facility in Louisville, Ky.

Media Contact:

Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com 
(617) 903-8783

FAQ

What is Talaris Therapeutics' stock symbol?

Talaris Therapeutics trades under the stock symbol 'TALS' on Nasdaq.

How much money did Talaris Therapeutics raise from its IPO?

Talaris Therapeutics raised approximately $150 million from its initial public offering.

When did Talaris Therapeutics' shares start trading?

Shares of Talaris Therapeutics started trading on May 7, 2021.

What was the offering price for Talaris Therapeutics' IPO?

The initial public offering price for Talaris Therapeutics was $17.00 per share.

What is the purpose of Talaris Therapeutics' IPO funds?

The funds from the IPO will be used to develop innovative cell therapies for organ transplantation and autoimmune diseases.